These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 8081414)

  • 1. The cytochrome P450 CYP2D6 allelic variant CYP2D6J and related polymorphisms in a European population.
    Armstrong M; Fairbrother K; Idle JR; Daly AK
    Pharmacogenetics; 1994 Apr; 4(2):73-81. PubMed ID: 8081414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism.
    Yokota H; Tamura S; Furuya H; Kimura S; Watanabe M; Kanazawa I; Kondo I; Gonzalez FJ
    Pharmacogenetics; 1993 Oct; 3(5):256-63. PubMed ID: 8287064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6.
    Wang SL; Huang JD; Lai MD; Liu BH; Lai ML
    Clin Pharmacol Ther; 1993 Apr; 53(4):410-8. PubMed ID: 8097442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation.
    Johansson I; Oscarson M; Yue QY; Bertilsson L; Sjöqvist F; Ingelman-Sundberg M
    Mol Pharmacol; 1994 Sep; 46(3):452-9. PubMed ID: 7935325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects.
    Dahl ML; Yue QY; Roh HK; Johansson I; Säwe J; Sjöqvist F; Bertilsson L
    Pharmacogenetics; 1995 Jun; 5(3):159-64. PubMed ID: 7550367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quinidine inhibition of debrisoquine S(+)-4- and 7-hydroxylations in Chinese of different CYP2D6 genotypes.
    Bertilsson L; Meese CO; Yue QY; Dahl ML; Ingelman-Sundberg M; Johansson I; Säwe J; Eichelbaum M
    Pharmacogenetics; 1993 Apr; 3(2):94-100. PubMed ID: 8100167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic basis for differences in debrisoquin polymorphism between a Spanish and other white populations.
    Agúndez JA; Martínez C; Ledesma MC; Ladona MG; Ladero JM; Benítez J
    Clin Pharmacol Ther; 1994 Apr; 55(4):412-7. PubMed ID: 7909282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Debrisoquine and mephenytoin oxidation in Sinhalese: a population study.
    Weerasuriya K; Jayakody RL; Smith CA; Wolf CR; Tucker GT; Lennard MS
    Br J Clin Pharmacol; 1994 Nov; 38(5):466-70. PubMed ID: 7893590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.
    Johansson I; Lundqvist E; Bertilsson L; Dahl ML; Sjöqvist F; Ingelman-Sundberg M
    Proc Natl Acad Sci U S A; 1993 Dec; 90(24):11825-9. PubMed ID: 7903454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population.
    Roh HK; Dahl ML; Johansson I; Ingelman-Sundberg M; Cha YN; Bertilsson L
    Pharmacogenetics; 1996 Oct; 6(5):441-7. PubMed ID: 8946476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis.
    Dahl ML; Johansson I; Bertilsson L; Ingelman-Sundberg M; Sjöqvist F
    J Pharmacol Exp Ther; 1995 Jul; 274(1):516-20. PubMed ID: 7616439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis.
    Broly F; Marez D; Sabbagh N; Legrand M; Millecamps S; Lo Guidice JM; Boone P; Meyer UA
    Pharmacogenetics; 1995 Dec; 5(6):373-84. PubMed ID: 8747409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes.
    Daly AK; Armstrong M; Monkman SC; Idle ME; Idle JR
    Pharmacogenetics; 1991 Oct; 1(1):33-41. PubMed ID: 1688241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population.
    Dahl ML; Johansson I; Palmertz MP; Ingelman-Sundberg M; Sjöqvist F
    Clin Pharmacol Ther; 1992 Jan; 51(1):12-7. PubMed ID: 1346258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PCR-based CYP2D6 genotyping for Finnish lung cancer patients.
    Hirvonen A; Husgafvel-Pursiainen K; Anttila S; Karjalainen A; Pelkonen O; Vainio H
    Pharmacogenetics; 1993 Feb; 3(1):19-27. PubMed ID: 8097947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles.
    Aklillu E; Persson I; Bertilsson L; Johansson I; Rodrigues F; Ingelman-Sundberg M
    J Pharmacol Exp Ther; 1996 Jul; 278(1):441-6. PubMed ID: 8764380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency of the variant allele CYP2D6(C) among North American Caucasian lung cancer patients and controls.
    Shaw GL; Weiffenbach B; Falk RT; Frame JN; Issaq HJ; Moir DT; Caporaso N
    Lung Cancer; 1997 May; 17(1):61-8. PubMed ID: 9194027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology.
    Steen VM; Andreassen OA; Daly AK; Tefre T; Børresen AL; Idle JR; Gulbrandsen AK
    Pharmacogenetics; 1995 Aug; 5(4):215-23. PubMed ID: 8528268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An association study of debrisoquine hydroxylase (CYP2D6) polymorphisms in schizophrenia.
    Dawson E; Powell JF; Nöthen MM; Crocq MA; Lanczik M; Körner J; Rietschel M; van Os J; Wright P; Gill M
    Psychiatr Genet; 1994; 4(4):215-8. PubMed ID: 7712118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Debrisoquin and S-mephenytoin hydroxylation phenotypes and CYP2D6 genotypes in an Estonian population.
    Marandi T; Dahl ML; Kiivet RA; Rägo L; Sjöqvist F
    Pharmacol Toxicol; 1996 May; 78(5):303-7. PubMed ID: 8737964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.